A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 1,500 Practices from Over 80 Countries have Participated in Market Scope Research
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Latest Industry News & Trends
5/1/2026
BreakingCataractCornealGlaucomaIOLLaserPharmaRetinaRevenueSurgical
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...
5/1/2026
BreakingRetinaStudy
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...
5/1/2026
BreakingDealsPharmaRetina
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
5/1/2026
BreakingPharmaRegulationRetina
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...
5/1/2026
BreakingCataractEquipmentEuropeRegulationRetinaSurgical
BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...
5/1/2026
BreakingCataractClinical TrialIOLPharma
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...
5/1/2026
BreakingCornealDry EyePharmaStudy
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...
5/1/2026
BreakingEuropeGene TherapyRegulationRetina
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate
Ray Therapeutics announced April 29 that the European Medicines Agency had granted Priority Medicines (PRIME) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)...
Join Market Scope Today
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.